Biopharma M&A Finally Seems To Be Waking Up

Investors are hoping that a surge in dealmaking will be a boon for the entire sector.

Stephen Taub June 22, 2023

Nicky Loh/Bloomberg

Another major healthcare company has agreed to acquire a fledgling biopharma company, and biopharma investors are hoping that an increase in dealmaking will help boost the stocks of the sector in general.On Tuesday, Eli Lilly agreed to buy DICE Therapeutics for $48 per share in

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

release/4.13.00 build:2025-12-17 Login